MedTrace Logo

Vasomotor Symptoms and Cardiovascular Control

NCT02202707 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-08-19

No results posted yet for this study

Summary

The purpose of this study is to preliminarily determine whether the frequency and/or severity of vasomotor symptoms (VMS) at baseline, and then after symptom reduction with gabapentin, relates to various cardiovascular control measures.

Conditions

Interventions

DRUG

Gabapentin

Study medication, gabapentin, will be distributed to all study participants and participants will be instructed as to how to take and titrate the medication dose. Participants will take gabapentin daily for up to six weeks.

Sponsors & Collaborators

Principal Investigators

  • J. Andrew Taylor, PhD · Spaulding Hospital Cambridge

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
58 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02202707 on ClinicalTrials.gov